KURA Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of -2301.55%. Kura Oncology, Inc.'s return on equity of -61.97% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 250.69%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 27.66%. Given that Kura Oncology, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Kura Oncology, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Kura Oncology, Inc. has a beta of 0.249, which suggesting that the stock is 75.095% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Kura Oncology, Inc.'s net income of -$74.1M is lower than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 7.91x versus 58.48x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of -12425.36%. Kura Oncology, Inc.'s return on equity of -61.97% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 250.69%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 333.37%. Given that Perspective Therapeutics, Inc. has higher upside potential than Kura Oncology, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Kura Oncology, Inc..

Kura Oncology, Inc. has a beta of 0.249, which suggesting that the stock is 75.095% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Kura Oncology, Inc.'s net income of -$74.1M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 7.91x versus 192.56x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of 12.65%. Kura Oncology, Inc.'s return on equity of -61.97% beat Electromed, Inc.'s return on equity of 18.89%.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 250.69%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25%. Given that Kura Oncology, Inc. has higher upside potential than Electromed, Inc., analysts believe Kura Oncology, Inc. is more attractive than Electromed, Inc..

Kura Oncology, Inc. has a beta of 0.249, which suggesting that the stock is 75.095% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Kura Oncology, Inc.'s net income of -$74.1M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 7.91x versus 3.84x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -357.19% compared to Kura Oncology, Inc.'s net margin of 13.19%. Kura Oncology, Inc.'s return on equity of -61.97% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Kura Oncology, Inc. has a consensus price target of $33.00, signalling upside risk potential of 250.69%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 450%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Kura Oncology, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Kura Oncology, Inc..

Kura Oncology, Inc. has a beta of 0.249, which suggesting that the stock is 75.095% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Kura Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kura Oncology, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Kura Oncology, Inc. quarterly revenues are $20.8M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Kura Oncology, Inc.'s net income of -$74.1M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Kura Oncology, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 28.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kura Oncology, Inc. is 7.91x versus 2.54x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.